NCT05287893View on ClinicalTrials.gov

Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 4, 2022

Primary Completion Date

September 26, 2022

Study Completion Date

September 26, 2022

Conditions
Malaria,FalciparumMalariaMalaria RecrudescenceParasitemiaProtozoan InfectionsParasitic Disease
Interventions
DRUG

Pyronaridine

Single dose

BIOLOGICAL

P. falciparum IBSM infection

Induced Blood Stage Malaria

Trial Locations (2)

4101

South Bank, Brisbane

4506

USC Clinical Trials, Morayfield, Brisbane

Sponsors

Collaborators (1)

Southern Star Research
All Listed Sponsors
collaborator

QIMR Berghofer Medical Research Institute

OTHER

collaborator

Southern Star Research

INDUSTRY

collaborator

Swiss BioQuant

INDUSTRY

collaborator

Children's Health Queensland Hospital and Health Service

UNKNOWN

lead

Medicines for Malaria Venture

OTHER

NCT05287893 - Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria | Biotech Hunter | Biotech Hunter